Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135717 | 1.00 | TDP1 (0.42) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL1162237 | 1.00 | TDP1 (0.42) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL11036766 | 1.00 | TDP1 (0.42) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL1162236 | 1.00 | TDP1 (0.42) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| Hydrochloric Acid SCHEMBL7952400 | 0.98 | TDP1 (0.41) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| Hydrochloric Acid SCHEMBL7952403 | 0.98 | TDP1 (0.41) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL2730560 | 0.86 | TDP1 (0.43) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL2519765 | 0.86 | TDP1 (0.43) | TDP1TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL1110727 | 0.83 | — | — | |
| SCHEMBL28496420 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118894909-B | Preparation method of natural cyclic peptide petrichorin C | 深圳乾延药物研发科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-118894909-A | Preparation method of natural cyclic peptide petrichorin C | 深圳乾延药物研发科技有限公司 | 2024-11-05 | — | — | CN | claimed |
| US-20080268077-A1 | Process for Strengthening the Barrier Function of Undamaged Skin | SYMRISE GMBH & CO. KG (DE) | 2008-10-30 | — | — | US | claimed |
| EP-1802272-A1 | PROCESS FOR STRENGTHENING THE BARRIER FUNCTION OF UNDAMAGED SKIN | Symrise GmbH & Co. KG (DE) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040349-A1 | PROCESS FOR STRENGTHENING THE BARRIER FUNCTION OF UNDAMAGED SKIN | SYMRISE GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | claimed |
| CN-118894909-B | Preparation method of natural cyclic peptide petrichorin C | 深圳乾延药物研发科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-118894909-A | Preparation method of natural cyclic peptide petrichorin C | 深圳乾延药物研发科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| WO-2023217590-A1 | POLYAMIDE MICROCAPSULES | FIRMENICH SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217589-A1 | POLYAMIDE MICROCAPSULES | FIRMENICH SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| CN-109401512-A | A kind of environment protection tile joint trimming agent and preparation method thereof | 赵砚霞 | 2019-03-01 | — | — | CN | disclosed |
| CN-102471349-B | Conformationally constrained, fully synthetic macrocyclic compounds | 波利弗尔股份公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-102471349-A | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG | 2012-05-23 | — | — | CN | disclosed |
| US-20060155021-A1 | Coating compositions containing rheology control agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-20060155146-A1 | Rheology control agents | AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) | 2006-07-13 | — | — | US | disclosed |
| WO-2006040349-A1 | PROCESS FOR STRENGTHENING THE BARRIER FUNCTION OF UNDAMAGED SKIN | SYMRISE GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-5962660-A | COMPOUND WHICH SUPPRESSES SELECTIN-MEDIATED CELLULAR ADHESION; FOR STABLE ANTIINFLAMMATORY AGENTS WITH BETTER BIOAVAILABILITY AND GREATER ACTIVITY WHICH ARE EASIER TO SYNTHESIZE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999010359-A2 | LIPOSOMIC BASED SIALYL LEWIS X MIMETICS | NOVARTIS AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| CN-1184483-A | Fucopeptides | NOWADIS LTD (CH) | 1998-06-10 | — | — | CN | disclosed |
| EP-0815127-A1 | FUCOPEPTIDES | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029339-A1 | FUCOPEPTIDES | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268077-A1 | Process for Strengthening the Barrier Function of Undamaged Skin | CERT1, CERS2, SGMS2 | TDP1 4715/4885TSHR 4810/4885MAPT 3655/4885 |
| US-20060155146-A1 | Rheology control agents | HCRTR1, HCRTR2, REL | TDP1 2448/4885TSHR 839/4885MAPT 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.